Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has been reaccredited by the Quality Oncology Practice Initiative (QOPI) Certification Program of the American Society of Clinical Oncology (ASCO). This program awards a three-year certification for outpatient hematology-oncology practices that meet nationally recognized standards for quality cancer care.
Research efforts to improve outcomes for people with ovarian cancer or glioma just got a boost in excess of $3 million. Noriyuki Kasahara, M.D., Ph.D., a researcher at Sylvester Comprehensive Cancer Center and professor of biology and pathology at the University of Miami Miller School of Medicine, and colleagues have received a $2.6 million NCI grant to support their unique technology to deliver targeted chemotherapy.
For Peruvian native Julio Barredo, M.D., director of children’s cancer programs at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, visits to his home country were often painful. He saw a cure rate of only 40 percent for the 700 children diagnosed annually with acute lymphoblastic leukemia, the most common childhood cancer. He knew that many of them were dying unnecessarily.
It was just a staircase, but to Patricia Emard, it could have been a mountain. With the help of the world-class oncologists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, she had triumphed over breast cancer, but it had taken all she could give. Two surgeries, chemotherapy and radiation had sapped her strength. She looked at the staircase and chose the elevator instead.
The Personalized Medicine Coalition (PMC), a prestigious group representing innovators, scientists, patients, providers and payers, has invited Sylvester Comprehensive Cancer Center to join its membership. “The invitation signifies their recognition of our strong work in this area,” said Jonathan C. Trent, M.D., Ph.D., Sylvester’s director of precision medicine.